Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Angiography Guidewire Obtains CFDA Registration Certificate


Shanghai, China – Recently, Shanghai MicroPort Medical Group Co., Ltd. ("MicroPort®") gained a China Food and Drug Administration ("CFDA") registration certificate for its in-house developed Hydrophilic Guide Wire For Peripheral Blood Vessel.
The Hydrophilic Guide Wire For Peripheral Blood Vessel is a sterile disposable surgical accessory, used for diagnosis of peripheral blood vessels or facilitating the insert of guiding catheter in interventional treatment. In Seldinger Technique, the Hydrophilic Guide Wire For Peripheral Blood Vessel is inserted into the vessel through a sheath to guide the catheter to reach the lesion vessel. In the process of introducing the catheter, the soft tip of the Hydrophilic Guide Wire For Peripheral Blood Vessel is always in front of the catheter, so under X-ray observation the physician can confirm the position of the catheter.
Hydrophilic Guide Wire For Peripheral Blood Vessel has hydrophilic coating on its surface. Compared to Super slip/Loach guide wires on the market, MicroPort®'s Hydrophilic Guide Wire For Peripheral Blood Vessel adopts improved formulation of coating material and coating process to guarantee excellent pushability and crossability of the Hydrophilic Guide Wire while making it easy for the operator to handle to reduce the incidence of complications. The CFDA approval of the Hydrophilic Guide Wire For Peripheral Blood Vessel further diversified MicroPort®'s product portfolio and expanded the field of application for MicroPort®'s surgical accessories.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Orthopedics Attends Elite Arthroplasty Course-EAC-ISKAA in India
[Next]:MicroPort® CardioFlow Attends 2017 PCR London Valves